The RCT published by Li was the only positive study; it reported a clear survival benefit in patients with GC treated with apatinib (a VEGFR2 inhibitor) compared with those receiving a placebo in terms of both OS (7.6 vs. 5.0 months, p = 0.0027) and PFS (2.8 vs. 1.9 months, p < 0.001), with an acceptable SAE rate [69]. This evidence concerns the gene KDR and gastric cancer.